April 02, 2026 05:25 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India | ‘Unsubstantial allegations’: Calcutta HC dismisses plea on ECI’s officer transfers in Bengal | Tennis icon Leander Paes joins BJP ahead of Bengal polls | 8 killed, several injured in crowd crush at Bihar temple in Nalanda | Trump signals exit from Iran war even as Strait of Hormuz remains shut: Report | Mystery death in Pakistan: JeM chief Masood Azhar’s brother found dead
Russia Sputnik V
Image Credit: Unsplash

Over 150 million Sputnik V doses distributed worldwide: Russia's Gamaleya Research

| @indiablooms | Sep 29, 2022, at 12:59 am

Moscow/IBNS: More than 150 million doses of the Sputnik V vaccine, developed by Russia’s Gamaleya Research Centre, have already been distributed around the world, including in the home country, the RGRC's Deputy Director Denis Logunov said on Wednesday.

"To date, based on a huge pool of data, more than 150 million doses of the Sputnik V vaccine have been produced and used in the world and in Russia.

"Huge safety and efficiency database has been accumulated," Logunov said at the international conference OpenBio-2022 in Russia’s science town of Koltsovo.

The accumulated data made it possible for Gamaleya Research Centre to expand the product line and develop Sputnik M, a vaccine for children aged 12-17, and produce a nasal version of the Sputnik V vaccine, which was registered on April 1, according to Logunov.

Clinical studies of the nasal vaccine showed a significant increase in antibody titer, the researcher said, adding that the Russian Health Ministry recommended two doses of the vaccine.

In addition, the research centre will soon begin clinical trials of a vaccine against the delta and omicron variants of COVID-19.

Meanwhile, the Ministry will allocate additional funding for a limited clinical trial for the development of a vaccine against the BA.5 coronavirus variant, Logunov noted.

At the same time, the effectiveness of the Sputnik V vaccine from getting infected by new strains of COVID-19 has decreased compared to the original strain, but the level of protection against lethality is still the same, he said.

Sputnik V, a combination vector vaccine for the prevention of COVID-19, was registered in Russia in August 2020.

Emergency mass distribution of the vaccine began in December 2020 in Russia and later in such countries as Argentina, Belarus, Hungary and Serbia.

As of January, the vaccine was authorized in more than 70 countries around the world.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.